CompletedPHASE1, PHASE2NCT01183312
Flumazenil for the Treatment of Primary Hypersomnia
Studying Idiopathic hypersomnia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lynn Marie Trotti
- Principal Investigator
- Lynn Marie Trotti, MDEmory University
- Intervention
- Flumazenil(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2012
Study locations (1)
- Emory Sleep Center, Atlanta, Georgia, United States
Collaborators
Georgia Research Alliance
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01183312 on ClinicalTrials.govOther trials for Idiopathic hypersomnia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07500090A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Harmony Biosciences Management, Inc.
- RECRUITINGNCT06732284Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance TaskCentre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT07006233A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic HypersomniaUniversity of Sydney
- RECRUITINGPHASE2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda
- RECRUITINGPHASE2, PHASE3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited